Tam, C. S., Brown, J. R., Kahl, B. S., Ghia, P., Giannopoulos, K., Jurczak, W., Šimkovič, M., Shadman, M., Österborg, A., Laurenti, L., Walker, P., Opat, S., Chan, H., Ciepluch, H., Greil, R., Tani, M., Trněný, M., Brander, D. M., Flinn, I. W., Grosicki, S., Verner, E., Tedeschi, A., Li, J., Tian, T., Zhou, L., Marimpietri, C., Paik, J. C., Cohen, A., Huang, J., Robak, T., & Hillmen, P. (2022). zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet oncology, 23(8), 1031–1043. http://access.bl.uk/ark:/81055/vdc_100159753041.0x00001e